MedTrace Logo

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

NCT01301833 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 462

Last updated 2026-01-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.

Conditions

Interventions

DRUG

teneligliptin

DRUG

glinide

DRUG

biguanide

DRUG

alpha-glucosidase inhibitor

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Takashi Kadowaki, Professor · Tokyo University

  • Kazuoki Kondo, MD · Tanabe Pharma Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301833 on ClinicalTrials.gov